Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT04037917 |
Other study ID # |
SP-001 |
Secondary ID |
|
Status |
Terminated |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
December 11, 2020 |
Est. completion date |
July 1, 2023 |
Study information
Verified date |
April 2022 |
Source |
CorNeat Vision Ltd. |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Study Name: The CorNeat EverPatch - a First-In-Man Clinical Study for demonstrating the
Safety of a Synthetic Tissue Substitute for concealment of artificial implants and glaucoma
tube shunts
Objective: The objective of this clinical trial is to demonstrate the Safety of the Corneat
Everpatch for concealment of artificial implants and glaucoma tube shunts
The study will consist 10 subjects requiring concealment of a glaucoma shunt or other
ophthalmic implant. Eligible subjects who signs an ICF will be enrolled to the study.
Subjects will be implanted with the Corneart EverPatch as part of a glaucoma shunt surgery or
during a corrective surgery to repair a breached conjunctiva over an implanted device.
Subjects will be monitored for a period of 12 months post-op during which follow up visits
will occur at 1 week, 1, 2, 3, 6, 9 & 12 months following surgery including clinical
examination of the operated eye using slit-lamp biomicroscopy and imaging using OCT or UBM
(will be performed only at the 6 & 12 months follow up visits).
Description:
Study Name: The CorNeat EverPatch - a First-In-Man Clinical Study for demonstrating the
Safety of a Synthetic Tissue Substitute for concealment of artificial implants and glaucoma
tube shunts
Objective: The objective of this clinical trial is to demonstrate the Safety of the Corneat
Everpatch for concealment of artificial implants and glaucoma tube shunts
Study endpoints:
Primary Safety Endpoint:
The frequency of all Unanticipated Adverse Device-related Events (UADE) or treatment-related
adverse events, during and following implantation and follow-up for up to 12 months will be
10% or less.
Effectiveness Endpoints:
Primary: Conjunctival integrity at the implantation site will be 90% or more. Secondary:
Stability in patch dimensions, less than 10% change (length, projected width and thickness)
measured by OCT after 1-week and follow-up for up to 12 months post-implantation in 90% of
the implanted patients.
Intended uses: The CorNeat EverPatch intended use is concealment of artificial ophthalmic
implants and glaucoma tube shunts.
The clinical investigation of the CorNeat EverPatch device is essential to validate its
safety and efficacy in its target implantation site and to substantiate regulatory clearance.
Clinical investigation of a medical device must be in compliance with Good Clinical Practice
as set forth in ISO 14155, which addresses good clinical practices for the design, conduct,
recording and reporting of clinical investigations carried out in human subjects for the
purpose of assessing the safety and performance of medical devices for regulatory purposes,
as well as applicable local laws and regulations.
Study Population: 10 subjects requiring concealment of artificial ophthalmic implants and
glaucoma tube shunts. Unilateral and bi-lateral. The device can be implanted in patients'
right or left eye (selection according to Principle Investigator's discretion).
Study Duration: Subjects will be followed-up for 12 months from device implantation date.
Visit Schedule:
• Screening: Day 0-7, Subjects will sign an Informed Consent Form (ICF) on screening visit
and baseline assessments for clinical condition, concomitant medication and medical history
data will be performed.
• Implantation: Implantation day will be recorded as day 0; enrollment day.
• Follow up visits at 1 week, 1, 2, 3, 6, 9 & 12-month post-op (total of 7 follow up visits).
At each follow up visit, subjects will be evaluated for: (i) conjunctival integrity; (ii)
device dimensions, (iii) clinical evaluation; (iv) device retention and (v) any clinically
necessary interim safety exam per PI decision. Additionally, at 6 & 12 months post-op,
subjects will undergo an imaging evaluation of the device's dimensions (either by UBM or
OCT).
Safety Assessment: A record of UADE as well as incidence and nature of Serious Adverse Events
(SAE) will be recorded. Incidence and nature of Adverse Events (AE) will be collected
throughout the study starting from implantation. The following types of events are outside of
this category:
(i) Adverse events related to the disease such as glaucoma and not caused by implant
concealment (ii) Adverse events related to the primary implant such as tube shunt blockage
not related to implant concealment